2D 3D
	ID	DDInter1435
	Drug Type	small molecule
	Molecular Formula	C20H15ClF3N5
	Molecular Weight	417.820
	CAS Number	1029044-16-3
	Description	Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor.[L7901] Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients.[L7901] While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence.[L7895] Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT.[A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]
	ATC Classification	L01EX15
IUPAC Name	5-({5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl}methyl)-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine
InChI	JGWRKYUXBBNENE-UHFFFAOYSA-N
Canonical SMILES	FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Useful Links	DrugBank ChEBI PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC